Top-News
Werbung

Attraktive Knock-Outs auf Sanofi SA

Typ Hebel Bid / Ask WKN
Call
5,0 1,77 € / 1,78 €
CL7G2W
Call
9,1 0,98 € / 0,99 €
SN567W
Typ Hebel Bid / Ask WKN
Put
5,3 1,66 € / 1,67 €
SH4RDM
Put
8,3 1,04 € / 1,05 €
SU0ZVW
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA
Pharmazeutika Frankreich

Sanofi SA News

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF
89,59 €
+0,26 €
+0,29%
15:31:04 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
1,25 Mrd.
Marktkapitalisierung *
111,43 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Euro Stoxx 50
IR-Website
zur Website
*Stand: 25.04.2024
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,52: ME87ZN

Ad-hocs

23.01.24 - GlobeNewswire
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Sanofi to acquire Inhibrx, Inc., adding potential best-​in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth strategy ...
09.01.24 - GlobeNewswire
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee Paris, January 9, 2024 . Brian Foard, a healthcare industry veteran and ...
21.12.23 - GlobeNewswire
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
15.12.23 - GlobeNewswire
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
Availability of the Q4 2023 Memorandum for modelling purposes
15.12.23 - GlobeNewswire
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
11.12.23 - GlobeNewswire
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
Statement on FTC challenge to proposed license agreement with Maze Therapeutics
11.12.23 - GlobeNewswire
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Sarclisa ® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-​eligible patients with newly diagnosed multiple myeloma versus ...
07.12.23 - GlobeNewswire
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Sarclisa ® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
07.12.23 - GlobeNewswire
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
R&D Day
27.11.23 - GlobeNewswire
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Dupixent ® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for ...
27.10.23 - GlobeNewswire
Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
Specialty Care growth, strong launch uptake of Beyfortus ® and ALTUVIIIO ® drive solid Q3 results
27.10.23 - GlobeNewswire
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
22.10.23 - GlobeNewswire
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Dupixent ® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
18.10.23 - GlobeNewswire
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
TZIELD ® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data ...
13.10.23 - GlobeNewswire
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
Late-​breaking amlitelimab Phase 2b data presented at EADV show potential best-​in-class profile in atopic dermatitis
03.10.23 - GlobeNewswire
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
Sanofi announces agreement for potential first-​in-class vaccine against extraintestinal pathogenic E. coli
26.09.23 - GlobeNewswire
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Dupixent ® (dupilumab) sBLA for t reatment of e osinophilic e sophagitis in c hildren a ged 1 to 11 accepted for FDA Priority Review
25.09.23 - GlobeNewswire
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
19.09.23 - GlobeNewswire
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
31.08.23 - GlobeNewswire
Press Release: Sanofi announces changes to its Executive Committee
Sanofi announces changes to its Executive Committee

Newssuche

Videos

newspaper
17.05.24 -5,31%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »